LncRNA SBF2-AS1 Promotes Diffuse Large B-Cell Lymphoma Growth by Regulating FGFR2 via Sponging miR-494-3p

References

• Lang JY, Ma K, Guo JX, Sun H. Oxidative stress induces B lymphocyte DNA damage and apoptosis by upregulating p66shc. Eur Rev Med Pharmacol Sci. 2018;22(4):1051–1060. doi:10.26355/eurrev_201802_1438829509254
   PubMed Web of Science ®Google Scholar
• Jabagi MJ, Goncalves A, Vey N, et al. Risk of hematologic malignant neoplasms after postoperative treatment of breast cancer. Cancers (Basel). 2019;11(10):1463. doi:10.3390/cancers11101463
   PubMed Web of Science ®Google Scholar
• Au KM, Wang AZ, Park SI. Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin’s lymphoma. Sci Adv. 2020;6(14):eaaz9798. doi:10.1126/sciadv.aaz979832270047
   PubMed Web of Science ®Google Scholar
• Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174–181. doi:10.1182/blood-2017-07-79398429061568
   PubMed Web of Science ®Google Scholar
• Tsuyama N, Sakata S, Baba S, et al. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood. 2017;130(4):489–500. doi:10.1182/blood-2016-12-75962128522442
   PubMed Web of Science ®Google Scholar
• Nakajima D, Okazaki N, Yamakawa H, et al. Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones. DNA Res. 2002;9(3):99–106. doi:10.1093/dnares/9.3.9912168954
   PubMed Web of Science ®Google Scholar
• Choudhari R, Sedano MJ, Harrison AL, et al. Long noncoding RNAs in cancer: from discovery to therapeutic targets. Adv Clin Chem. 2020;95:105–147.32122521
   PubMed Web of Science ®Google Scholar
• Yang F, Zhang L, Huo XS, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology. 2011;54(5):1679–1689. doi:10.1002/hep.2456321769904
   PubMed Web of Science ®Google Scholar
• Abba MC, Gong T, Lu Y, et al. A molecular portrait of high-grade ductal carcinoma in situ. Cancer Res. 2015;75(18):3980–3990. doi:10.1158/0008-5472.CAN-15-050626249178
   PubMed Web of Science ®Google Scholar
• Fang Z, Xu C, Li Y, et al. A feed-forward regulatory loop between androgen receptor and PlncRNA-1 promotes prostate cancer progression. Cancer Lett. 2016;374(1):62–74. doi:10.1016/j.canlet.2016.01.03326808578
   PubMed Web of Science ®Google Scholar
• Santos JMO, Peixoto da Silva S, Gil da Costa RM, Medeiros R. The emerging role of microRNAs and other non-coding RNAs in cancer cachexia. Cancers (Basel). 2020;12(4):1004. doi:10.3390/cancers12041004
   PubMed Web of Science ®Google Scholar
• Peng W, Feng J. Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma. Biomed Pharmacother. 2016;77:65–71. doi:10.1016/j.biopha.2015.12.00126796267
   PubMed Web of Science ®Google Scholar
• Liang C, Yue C, Liang C. The long non-coding RNA SBF2-AS1 exerts oncogenic functions in gastric cancer by targeting the miR-302b-3p/E2F transcription factor 3 axis [Retraction]. Onco Targets Ther. 2020;13:2523. doi:10.2147/OTT.S25458732280237
   PubMed Web of Science ®Google Scholar
• Xia W, Liu Y, Cheng T, et al. Correction to: down-regulated lncRNA SBF2-AS1 inhibits tumorigenesis and progression of breast cancer by sponging microRNA-143 and repressing RRS1. J Exp Clin Cancer Res. 2020;39(1):60. doi:10.1186/s13046-020-01563-532264934
   PubMed Web of Science ®Google Scholar
• Hua YQ, Zhu YD, Xie GQ, et al. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1. Aging (Albany NY). 2019;11(20):8860–8878. doi:10.18632/aging.10230731619579
   PubMedGoogle Scholar
• Arzuaga-Mendez J, Prieto-Fernandez E, Lopez-Lopez E, et al. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: a systematic review. Crit Rev Oncol Hematol. 2019;139:7–15. doi:10.1016/j.critrevonc.2019.04.01331112884
   PubMed Web of Science ®Google Scholar
• Lacy SE, Barrans SL, Beer PA, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020;135(20):1759–1771. doi:10.1182/blood.201900353532187361
   PubMed Web of Science ®Google Scholar
• Opinto G, Vegliante MC, Negri A, et al. The tumor microenvironment of DLBCL in the computational era. Front Oncol. 2020;10:351. doi:10.3389/fonc.2020.0035132296632
   PubMed Web of Science ®Google Scholar
• Huang Z, Zhou JK, Peng Y, et al. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020;19(1):77. doi:10.1186/s12943-020-01188-432295598
   PubMed Web of Science ®Google Scholar
• Liu J, Liu ZX, Wu QN, et al. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020;11(1):1507. doi:10.1038/s41467-020-15112-332198345
   PubMed Web of Science ®Google Scholar
• Brazao TF, Johnson JS, Muller J, et al. Long noncoding RNAs in B-cell development and activation. Blood. 2016;128(7):e10–19. doi:10.1182/blood-2015-11-68084327381906
   PubMed Web of Science ®Google Scholar
• Deng L, Jiang L, Tseng KF, et al. Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma. Cancer Biomark. 2018;23(2):157–164. doi:10.3233/CBM-16022130175971
   PubMed Web of Science ®Google Scholar
• Wang W, Hu W, Wang Y, et al. Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA. Mol Cancer. 2020;19(1):18. doi:10.1186/s12943-020-1132-x31996265
   PubMed Web of Science ®Google Scholar
• Hu YP, Jin YP, Wu XS, et al. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis. Mol Cancer. 2019;18(1):167. doi:10.1186/s12943-019-1097-931752906
   PubMed Web of Science ®Google Scholar
• Hilberg F, Tontsch-Grunt U, Baum A, et al. Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases. J Pharmacol Exp Ther. 2018;364(3):494–503. doi:10.1124/jpet.117.24412929263244
   PubMed Web of Science ®Google Scholar
• Lamberti D, Cristinziano G, Porru M, et al. HSP90 inhibition drives degradation of FGFR2 fusion proteins: implications for treatment of cholangiocarcinoma. Hepatology. 2019;69(1):131–142. doi:10.1002/hep.3012730067876
   PubMed Web of Science ®Google Scholar